Evox Therapeutics Limited CEO Tony de Fougerolles has told Scrip that the UK firm's exosome expertise, strong pipeline and big pharma partnerships can help it become a 'unicorn' billion-dollar biotech.
He was speaking as Evox concluded a series C financing round that raised £69.2m ($95.4m) led by long-time backer Redmile...